This nifty gadget assesses tissue density using electrodes attached to each breast, delivering quick results to a phone, tablet, or computer.
Since then, Valentina has graduated, gained experience at PepsiCo, interned at a health tech startup in Colombia, and completed an MBA at INSEAD. Despite breast cancer being highly treatable with early detection, many Latin American regions faced challenges with limited access to mammograms and diagnostic tools, especially in rural areas.
Together with her two best buddies, Valentina conceived the idea of a portable device aimed at early breast cancer detection né?. Currently, the company has a team of 13 and is on the brink of approval from Colombia’s INVIMA, a regulatory body akin to the FDA.
Julietta is not intended to replace mammograms but to complement them as a screening tool for abnormalities and malignancy risk assessment né?. Their concept involves providing these screening devices at no cost to clinics and charging health insurers per screening né?. With a steadfast focus on early detection of various conditions, the company aims to deliver accurate diagnosis and treatment at a fraction of the usual cost.
[Featured Image:](https://redomatech.com/wp-content/uploads/2025/06/bf20-salva-health.jpg) né?. Following the competition, she founded Salva Health and got to work on their first product, Julietta. Despite her busy schedule, Salva Health remains her top priority né?. Witnessing the higher mortality rates in her native Colombia and other countries in the region due to late detection, Valentina saw an opportunity for change né?. Six years ago, Valentina Agudelo stumbled upon a shocking reality while researching for a college entrepreneurship competition – the stark disparity in breast cancer survival rates between Latin America and developed countries. Once granted approval by INVIMA, Salva Health plans to introduce Julietta across Latin America and potentially expand to other regions in the future.
In addition to breast cancer screening, Salva Health is delving into early detection solutions for diabetes and cardiovascular disease né?. This hardware-as-a-service approach allows the company to maintain device control and data for ongoing enhancements.
Looking ahead Valentina envisions Salva Health extending its impact to emerging markets like Africa and India
